RxDoctor Payments Data

Tchido Yao, NP

Psychiatric/Mental Health · Kent, WANPI 1922662055

Payments from drug & device makers

$574in general payments, 2019–2025

Across 26 payments — averaging $22.06 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Otsuka America Pharmaceutical, Inc.$143
  • Tris Pharma Inc$112
  • Alkermes, Inc.$95
  • Johnson & Johnson$69
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$40
  • AbbVie$30
  • plus $84 from 4 others

What the payments were for

  • Food & beverage$574100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$574 in reported general payments places this provider in the 65th percentile of 931 psychiatric/mental health providers in Washington.

See all psychiatric/mental health providers in Washington

Medicare billing

Part B allowed, 2024
$10,675
Medicare patients
26
Services billed
109

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Invega SustennaPaliperidone Palmitate12$38,116
Methylphenidate ErMethylphenidate Hcl29$2,351
Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine61$1,927
Dextroamphetamine-Amphet ErDextroamphetamine/Amphetamine26$1,261
Methylphenidate Hcl43$777
Clonazepam54$671
Olanzapine59$620
Lamotrigine39$577
Lithium Carbonate58$508
Fluoxetine Hcl15$377
Hydroxyzine Hcl15$332
Eszopiclone17$320
Bupropion XlBupropion Hcl14$261
Quetiapine Fumarate19$224
Alprazolam41$210

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonInvega Sustenna$69$38,11612 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 931 psychiatric/mental health providers in Washington.

Other psychiatric/mental health in Kent

See the full list for Washington

Where these figures come from

Is this you, or does something look wrong? →